- Review
The Pursuit of the “Inside” of the Amyloid Hypothesis—Is C99 a Promising Therapeutic Target for Alzheimer’s Disease?
- Nobumasa Takasugi,
- Masato Komai,
- Nanaka Kaneshiro,
- Atsuya Ikeda,
- Yuji Kamikubo and
- Takashi Uehara
Aducanumab, co-developed by Eisai (Japan) and Biogen (U.S.), has received Food and Drug Administration approval for treating Alzheimer’s disease (AD). In addition, its successor antibody, lecanemab, has been approved. These antibodies target th...